Survodutide vs Mazdutide
Both are GLP-1/glucagon dual agonists; compare obesity evidence, liver endpoints, populations, doses and regulatory stage.
| Attribute | Survodutide | Mazdutide |
|---|---|---|
| Human evidence | Published Phase 3 SYNCHRONIZE-1 evidence now shows significant weight loss in adults with obesity, alongside late-stage MASLD/MASH evidence. Survodutide remains investigational. | Phase 3 GLORY trials show substantial weight loss in Chinese adults. Mazdutide received its first approval in China in June 2025 for long-term weight management and later for type 2 diabetes. |
| Research focus | Obesity, MASH, liver fibrosis, cardiovascular outcomes | Obesity, type 2 diabetes, metabolic liver disease, obstructive sleep apnoea |
| Regulatory status | Investigational; no general marketing authorisation for obesity or MASH identified in the reviewed jurisdictions. | First approved in China in June 2025 for chronic weight management in qualifying adults; later approved there for glycaemic control in type 2 diabetes. Not a globally authorised medicine. |
| Route / formulation | Evidence is from trial-grade once-weekly subcutaneous product with protocol-driven escalation. | Clinical evidence concerns regulated trial/authorised subcutaneous formulations. Research-market material cannot be assumed equivalent. |
Why these are compared
These compounds appear in the weight & metabolic liver research evidence landscape, but they are not interchangeable. Survodutide is dual glucagon receptor / glp-1 receptor agonist peptide studied in obesity, mash, liver fibrosis, cardiovascular outcomes; Mazdutide is dual glucagon receptor / glp-1 receptor agonist peptide studied in obesity, type 2 diabetes, metabolic liver disease, obstructive sleep apnoea. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Survodutide: Published Phase 3 human evidence; investigational.
Mazdutide: Approved in China for defined indications — jurisdiction specific.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.